Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244

被引:21
作者
Ammoun, Sylwia [1 ]
Ristic, Natalia [1 ]
Matthies, Cordula [2 ]
Hilton, David A. [3 ]
Hanemann, C. Oliver [1 ]
机构
[1] Univ Plymouth, Pennsula Coll Med & Dent, Plymouth PL6 8BU, Devon, England
[2] Klinikum Bavanan Julius Maximilians Univ, Neurochirurg Klin & Poliklin, D-97080 Wurzburg, Germany
[3] Derriford Hosp, Dept Neuropathol, Plymouth PL6 8DH, Devon, England
关键词
Schwannoma; Merlin-deficient tumors; Targeted therapy; AZD6244; KINASE KINASE-1/2 INHIBITOR; SIGNAL-REGULATED KINASE; RAF/MEK/ERK PATHWAY; GROWTH; MERLIN; MYELINATION; ARRY-142886; APOPTOSIS; PROTEINS;
D O I
10.1016/j.nbd.2009.09.017
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Deficiency of the tumor suppressor merlin leads to the development of multiple tumors of the nervous system, such as schwannomas, meningiomas, and ependymomas. Due to the benign character of these tumors, classical chemotherapy is ineffective. Current therapies, surgery. and radiosurgery are local and quite invasive, thus new systemic treatments are required. We have previously described the Raf/mitogen-activated kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway activation and its role in schwannoma growth Here, we targeted MEK1/2 known as a convergence point for multiple cascades towards ERK1/2 activation and cell proliferation, using MEK1/2 inhibitor AZD6244 (ARRY-142886; Astra Zeneca). We show that AZD6244 at low concentration completely abolished platelet-derived growth factor-DD-mediated ERK1/2 activation and cell proliferation in human primary schwannoma cells Moreover, this drug was not toxic for either schwannoma or Schwann cells and has been reported to be safe with tolerable side effects Thus, AZD6244 can be considered as a drug candidate for schwannoma treatment. (C) 2009 Elsevier Inc All rights reserved
引用
收藏
页码:141 / 146
页数:6
相关论文
共 27 条
[1]   Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers [J].
Adjei, Alex A. ;
Cohen, Roger B. ;
Franklin, Wilbur ;
Morris, Clive ;
Wilson, David ;
Molina, Julian R. ;
Hanson, Lorelei J. ;
Gore, Lia ;
Chow, Laura ;
Leong, Stephen ;
Maloney, Lara ;
Gordon, Gilad ;
Simmons, Heidi ;
Marlow, Allison ;
Litwiler, Kevin ;
Brown, Suzy ;
Poch, Gregory ;
Kane, Katie ;
Haney, Jerry ;
Eckhardt, S. Gail .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2139-2146
[2]   Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma [J].
Ammoun, Sylwia ;
Flaiz, Christine ;
Ristic, Natalia ;
Schuldt, Jennifer ;
Hanemann, C. Oliver .
CANCER RESEARCH, 2008, 68 (13) :5236-5245
[3]   Postnatal Schwann cell proliferation but not myelination is strictly and uniquely dependent on cyclin-dependent kinase 4 (cdk4) [J].
Atanasoski, Suzana ;
Boentert, Matthias ;
De Ventura, Lukas ;
Pohl, Hartinut ;
Baranek, Constanze ;
Beier, Konstantin ;
Young, Peter ;
Barbacid, Mariano ;
Suter, Ueli .
MOLECULAR AND CELLULAR NEUROSCIENCE, 2008, 37 (03) :519-527
[4]   ERM proteins and merlin: Integrators at the cell cortex [J].
Bretscher, A ;
Edwards, K ;
Fehon, RG .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (08) :586-599
[5]   Increase of MCP-1 (CCL2) in myelin mutant Schwann cells is mediated by MEK-ERK signaling pathway [J].
Fischer, Stefan ;
Weisiiaupt, Andreas ;
Troppmair, Jakob ;
Martini, Rudolf .
GLIA, 2008, 56 (08) :836-843
[6]   Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells [J].
Flaiz, C. ;
Utermark, T. ;
Parkinson, D. B. ;
Poetsch, A. ;
Hanemann, C. O. .
GLIA, 2008, 56 (05) :506-515
[7]   BRAF V600E disrupts AZD6244-Induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins [J].
Friday, Bret B. ;
Yu, Chunrong ;
Dy, Grace K. ;
Smith, Paul D. ;
Wang, Liang ;
Thibodeau, Stephen N. ;
Adjei, Alex A. .
CANCER RESEARCH, 2008, 68 (15) :6145-6153
[8]   Cotargeting survival signaling pathways in cancer [J].
Grant, Steven .
JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (09) :3003-3006
[9]   Differential gene expression between human schwannoma and control Schwann cells [J].
Hanemann, C. O. ;
Bartelt-Kirbach, B. ;
Diebold, R. ;
Kaempchen, K. ;
Langmesser, S. ;
Utermark, T. .
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2006, 32 (06) :605-614
[10]   Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation [J].
Hansen, JR ;
Roehm, PC ;
Chatterjee, P ;
Green, SH .
GLIA, 2006, 53 (06) :593-600